CI Stock Analysis — Cigna
Sector: Healthcare
AI Verdict
Cigna trades at 9.4x next year's earnings while analysts expect +36.3% EPS growth — that's cheap for the growth on offer if its scale and integrated pharmacy moat keep costs in check.
Competitive Moat
Cigna operates as a diversified health insurer with a large employer and government client base, giving it scale advantages in negotiating provider rates and managing medical costs. Its integrated pharmacy benefit management arm, Evernorth, creates cross-selling opportunities and data-driven care management that are difficult for smaller rivals to replicate.
Summary
Cigna is trading at just 9.4x forward earnings with analyst consensus calling for 36.3% EPS growth next year.
Where It Stands
The stock is down -14.90% over the past year, its RSI is a neutral 56.9, and it trades at 9.4x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 56.9 — Neutral
- Trailing P/E: 12.8x
- Forward P/E: 9.4x
- PEG Ratio: 0.35
- Earnings Growth: +0.4%
- Revenue Growth: +0.1%
- Market Cap: $75.1B
- Dividend Yield: 0.02%
- 1-Year Return: -14.90%
- 52-Week High: $350.00
- 52-Week Low: $239.51
Analyst Consensus
29 Buy · 5 Hold · 0 Sell (34 analysts)
Bull Case
With analysts expecting 36.3% EPS growth and a forward P/E of 9.4x, you’re getting a lot of growth for a bargain multiple.
Bear Case
If the P/E reverts to a sector median of 22x but earnings disappoint, the stock could remain stuck or even fall further given its -14.90% 1-year return.
Catalyst to Watch
Watch for upcoming quarterly earnings and medical cost trend disclosures — a positive surprise on cost control could drive a rerating.